Results 31 to 40 of about 99,732 (351)

A synthetic biology approach for a vaccine platform against known and newly emerging serotypes of bluetongue virus [PDF]

, 2014
Bluetongue is one of the major infectious diseases of ruminants and is caused by Bluetongue virus (BTV), an arbovirus existing in nature in at least 26 distinct serotypes. Here, we describe the development of a vaccine platform for BTV.
Brunet, Silvie, Hamers, Claude, Hudelet, Pascal, Nunes, Sandro Filipe, Palmarini, Massimo, Ratinier, Maxime, Shaw, Andrew   +6 more
core   +2 more sources

Generation of DelNS1 Influenza Viruses: a Strategy for Optimizing Live Attenuated Influenza Vaccines

mBio, 2019
Nonstructural protein 1 (NS1) of influenza virus is a key virulence element with multifunctional roles in virus replication and a potent antagonist of host immune response.
Pui Wang, Min Zheng, Siu-Ying Lau, Pin Chen, Bobo Wing-Yee Mok, Siwen Liu, Honglian Liu, Xiaofeng Huang, Conor J. Cremin, Wenjun Song, Yixin Chen, Yik-Chun Wong, Haode Huang, Kelvin Kai-Wong To, Zhiwei Chen, Ningshao Xia, Kwok-Yung Yuen, Honglin Chen   +17 more
doaj   +1 more source

Zika Virus Attenuation by Codon Pair Deoptimization Induces Sterilizing Immunity in Mouse Models. [PDF]

, 2018
Zika virus (ZIKV) infection during the large epidemics in the Americas is related to congenital abnormities or fetal demise. To date, there is no vaccine, antiviral drug, or other modality available to prevent or treat Zika virus infection.
Hu, Q, Ke, X, Li, P, Liu, Y, Luo, D, Miao, Y, Sun, J, Tan, Z, Wang, H, Wang, T, Xu, F, Zhang, Y, Zheng, Z   +12 more
core   +1 more source

Repurposing mucosal delivery devices for live attenuated tuberculosis vaccines

Frontiers in Immunology, 2023
Tuberculosis (TB) remains one of the most lethal infectious diseases globally. The only TB vaccine approved by the World Health Organization, Bacille Calmette-Guérin (BCG), protects children against severe and disseminated TB but provides limited ...
Munish Puri, Munish Puri, Socorro Miranda-Hernandez, Selvakumar Subbian, Andreas Kupz   +4 more
doaj   +1 more source

Live attenuated oral cholera vaccines

Expert Review of Vaccines, 2006
Live, orally administered, attenuated vaccine strains of Vibrio cholerae have many theoretical advantages over killed vaccines. A single oral inoculation could result in intestinal colonization and rapid immune responses, obviating the need for repetitive dosing. Live V.
Edward T, Ryan, Stephen B, Calderwood, Firdausi, Qadri   +2 more
openaire   +2 more sources

Protective immunity against Trypanosoma cruzi [PDF]

, 2009
Upon infection, Trypanosoma cruzi triggers a strong immune response that has both protective and pathological consequences. In this work, several important questions regarding protective immunity are reviewed.
Basombrío, Miguel Ángel Manuel, Padilla, Ángel Marcelo, Parodi Ramoneda, Cecilia María   +2 more
core   +1 more source

Influenza and memory T cells : how to awake the force [PDF]

, 2016
Annual influenza vaccination is an effective way to prevent human influenza. Current vaccines are mainly focused on eliciting a strain-matched humoral immune response, requiring yearly updates, and do not provide protection for all vaccinated individuals.
Glezen, Hartshorn, Hufford, Jin, Jordan, Luo, Mosmann, Razvi, Topham, Topham, Topham, Von Andrian, Wijburg   +12 more
core   +3 more sources

Impact of inactivated poliovirus vaccine on mucosal immunity: implications for the polio eradication endgame. [PDF]

, 2015
The polio eradication endgame aims to bring transmission of all polioviruses to a halt. To achieve this aim, it is essential to block viral replication in individuals via induction of a robust mucosal immune response. Although it has long been recognized
Anis E, Davis DC, Edward PK Parker, Ghendon YZ, Glezen WP, Glezen WP, Herremans MM, Herremans TM, Hovi T, Kathleen M O’Reilly, Margarita Pons-Salort, Marine WM, Natalie A Molodecky, Nicholas C Grassly, Ogra PL, Wehrle PF, WHO Collaborative Study Group on Oral and Inactivated Poliovirus Vaccines   +16 more
core   +3 more sources

Live-attenuated vaccination in patients with inflammatory bowel disease while continuing or after elective switch to vedolizumab [PDF]

Intestinal Research
Background/Aims Vedolizumab (VDZ) is a gut-selective agent with a favorable safety profile. We aimed to assess the feasibility of elective switch from other advanced therapies to VDZ and subsequent live-attenuated vaccination while continuing VDZ in ...
Hisashi Shiga, Hiroshi Nagai, Yusuke Shimoyama, Takeo Naito, Rintaro Moroi, Yoichi Kakuta, Yoshitaka Kinouchi, Atsushi Masamune   +7 more
doaj   +1 more source

Vaccines against toxoplasma gondii : challenges and opportunities [PDF]

, 2009
Development of vaccines against Toxoplasma gondii infection in humans is of high priority, given the high burden of disease in some areas of the world like South America, and the lack of effective drugs with few adverse effects.
Aliberti J, Angus CW, Aosai F, Aosai F, Awan KJ, Beghetto E, Bommireddy R, Bonenfant C, Boyle JP, Brinkmann V, Buxton D, Bülow R, Caetano BC, Conacher M, Cong H, Cong H, Constant SL, Couper KN, Craig W Roberts, Cui YL, Cuppari AF, Curtsinger JM, Curtsinger JM, Cutchins EC, Darcy F, Dautu G, Debard N, Debierre-Grockiego F, DeGregorio E, Denkers EY, Desolme B, Duquesne V, Echeverria PC, Elisabeth Förster-Waldl, Erik Jongert, Escajadillo A, Eskild Petersen, Fachado A, Fachado A, Flori P, Fox B, Frenkel JK, Garcia JL, Garcia JL, Gatkowska J, Gazzinelli R, Gazzinelli RT, Golkar M, Hakim FT, Igarashi M, Innes EA, Ishii K, Ishii KJ, Ismael AB, Ismael AB, Johnson LL, Jongert E, Jongert E, Jongert E, Kasper LH, Khan IA, Kijlstra A, Kodjikian L, Krahenbuhl JL, Kringel H, Letscher-Bru V, Letscher-Bru V, Leyva R, Lindsay DS, Liu Q, Lourenco EV, Lourenço EV, Martin V, McLeod R, Mishima M, Mishima M, Mohamed RM, Mévélec MN, Mévélec MN, Nicola Gargano, Nielsen HV, Nielsen HV, Petersen E, Petrovsky N, Pettersen EK, Pfefferkorn ER, Qu D, Reikvam A, Roque-Resendiz JL, Sabin AB, Sayles PC, Schaap D, Scorza T, Siachoque H, Sibley LD, Silveira C, Stanley AC, Stockinger B, Supply P, Taneja V, Vandepapelierea P, Velge-Roussel F, Velge-Roussel F, Vercammen M, Vogel N, Vyas JM, Waldeland H, Wang H, Wilkins MF, Williams MA, Xue M, Xue M, Yang CD, Yarovinsky F, Zenner L, Zhang G, Zhang J, Zimmermann S   +117 more
core   +3 more sources